The current treatment situation and definitions of a cure for chronic HBV infection. (January 2016)

• Record Type: Journal Article
• Authors: Demma, Shirin; Dusheiko, Geoffrey
• Is Part Of: Future virology. Volume 11:Number 1(2016)
• Page Start: 79
• Page End: 92
• Publication Date: 2016-01
• Subjects: antiviral therapy -- entecavir -- HBsAg -- hepatitis B -- hepatitis B surface antigen -- hepatitis B vaccination -- immunomodulatory therapy -- nucleoside analogs; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl.15.93
• Languages: English
• ISSNs: 1746-0794

Abstract

HBV vaccination, while effective in reducing incident chronic disease in endemic regions, will not have the desired impact on the rates of end-stage liver disease in chronically infected persons. Over three decades, IFN-α and nucleoside analogs have reduced the morbidity from the disease. A large reservoir of chronic infection remains. The natural history of HBV infection is still being defined. Understanding the interactions between HBV and the host will be fundamental to achieving higher rates of cure. Curing hepatitis B will require several steps for either eradication, or a functional cure in the host. It is unclear whether covently closed circular DNA chromatin would need to be cleared to cure hepatitis B, or whether low threshold levels would slow the disease.